You have read all your free articles, to continue reading subscribe to read the rest of this content.
Three members of the company's Board, Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl, has decided to step down from the Board with immediate effect. Following the decisions to discontinue the PARADIGME study for Betalutin, restructure the company and appoint Carnegie Investment Bank toAlready a subscriber Login You have read…
Nanoform Finland will convene an extraordinary general meeting (EGM) on November 17 to elect Jeanne Thoma as a new board member. “Following the successful completion of our clinical trial and commercial expansion, we’ve reached an exciting point in Nanoform’s growth trajectory and are deligAlready a subscriber Login You have read…
The company has appointed Dr Lars Nieba as Chief Technology Officer and a member of the executive management team. Dr Nieba brings 20 years of leadership experience in the development of multiple pharmaceutical product candidates and innovative technologies. His role at Nordic Nanovector will be Already a subscriber Login You…
On August 1st, Tomer Feffer started his position as CEO of Bayer Sweden and of the company's pharmaceutical division in Scandinavia. "It is an honor and a privilege to take over as CEO of Bayer Sweden and become a part of the next phase of a journey that began 71…
